19 September 2025

N4 Pharma plc

("N4 Pharma" or the "Company")

Notice of Results

Analyst Briefing and Investor Presentation

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, will announce its unaudited interim results for the six months ended 30 June 2025 on Thursday, 25 September 2025 and hold the following analyst briefing and investor presentation.

Analyst briefing

An online briefing for analysts will be hosted by Nigel Theobald, Chief Executive Officer, at 9.30 am on Thursday, 25 September 2025, to review the interim results. Analysts wishing to attend should contact Sarah Hollins at Northstar Communications at [email protected].

Investor presentation

An investor presentation to cover the interim results will be held at 2.00 pm on Thursday, 25 September 2025.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 am on Wednesday, 24 September 2025 or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet N4 Pharma plc via:

https://www.investormeetcompany.com/n4-pharma-plc/register-investor

Investors who already follow N4 Pharma plc on the Investor Meet Company platform will automatically be invited.

- Ends -

For more information please contact:

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.

For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.